Filtered By:
Management: Marketing

This page shows you your search results in order of date. This is page number 20.

Order by Relevance | Date

Total 564 results found since Jan 2013.

Should you wear anti-aging lingerie? Episode 112
Please support the Beauty Brains by signing up for a free audio book at Audible.com. Click here to get your free audio book. Do supplements improve skin? Link I saw this story published on the cosmetic surgery times website asking the question whether nutricosmetics is real science or scientific rhetoric. Or as we called it a few shows back “sciencesplotation”. First a definition of nutricosmetics. These are supplements that supposedly can help support skin, hair and nail health. It is a group of products that play into the old saying, you are what you eat. In cosmetic industry marketing speak it’s referred to as th...
Source: thebeautybrains.com - December 15, 2015 Category: Consumer Health News Authors: Randy SchuellerDiscover the beauty and cosmetic products you should use and avoid Source Type: blogs

FDA Wants to Know if Your Cigarette is Defective, Damaged, or Contaminated, But Doesn't Care if It Kills You
In a communication I thought I would never see from a public health agency, the Center for Tobacco Products (CTP) of the Food and Drug Administration (FDA) has alerted consumers to notify them if their cigarettes are defective or contaminated, but not if they cause severe adverse health effects, like cancer, heart disease, lung disease, stroke, or death.The tweet from CTP states: "There's no safe #tobacco product, but if it’s defective, damaged, or contaminated, let us know." It then refers consumers to a link where they can report the defective product.However, the FDA provided no link to report the actual, devastating ...
Source: The Rest of the Story: Tobacco News Analysis and Commentary - December 14, 2015 Category: Addiction Source Type: blogs

Is Hoof Maker cream for horses really good for your nails? Episode 111
This study is often quoted as saying it worked better than or as well as 4% hydroquinone but 4 weeks is not long enough to judge that and again, and this was not about hexylresorcinol itself .” Finally, the website Truth in Aging says… ”HR’s ability to target pathways in the skin that lead to hyperpigmentation has propelled it into the skin lightening ingredient category. There is also thought that Hexylresorcinol has more benefits as well, including an ability to reduce the appearance of fine lines and wrinkles, increase protection against UVB and UVA rays, and improve the skin’s barrier against pollution an...
Source: thebeautybrains.com - December 8, 2015 Category: Consumer Health News Authors: Perry RomanowskiDiscover the beauty and cosmetic products you should use and avoid Source Type: blogs

Senate Finance Committee Releases Results of Investigation Into Gilead’s Pricing Strategy for Hepatitis-C Drugs
Discussion The Gilead example does not represent the life science community well, and highlights the need to put extra thought into the way drugs are priced. Gilead clearly was allowing marketing to drive the pricing ship and displayed what could be considered an almost reckless disregard for availability and affordability. Pharmaceutical companies can, and should, attempt to maximize their profit, but should consider doing so in a way that ensures availability and affordability for patients and payers alike. While there is no clear answer to the drug pricing dilemma we currently face, perhaps more thought and research s...
Source: Policy and Medicine - December 2, 2015 Category: American Health Authors: Thomas Sullivan - Policy & Medicine Writing Staff Source Type: blogs

Pharmaceutical Pricing – A Reminder of the Value Equation
We previously wrote about the actions Congress is taking to "combat rising prescription drug prices," and the rhetoric politicians of all stripes are using in an attempt to force public opinion on their side. HHS has announced a pharmaceutical pricing forum set for November 20, Congress has committees on both sides working toward a "solution," and Hillary Clinton has said that if she is elected president, she would "demand a stop to excessive profiteering and marketing" by the drug industry. Often left out those discussions includes the value of medications, PhRMA has recently released a forty-deck slideshow that addresse...
Source: Policy and Medicine - November 25, 2015 Category: American Health Authors: Thomas Sullivan - Policy & Medicine Writing Staff Source Type: blogs

An open letter to MPs of Malaysia
13 November 2015 An open letter to the Members of Parliament of Malaysia  We, the undersigned medical professional bodies and non-governmental organisations, would like to register our concern regarding the increasing presence of electronic cigarettes and vaping in our society. We note with dismay the Cabinet’s rejection of the Ministry of Health’s proposal to ban the sales and use of electronic cigarettes.  1. Malaysia proudly signed and ratified the World Health Organisation’s Framework Convention on Tobacco Control (FCTC). This is a reflection of the nation’s commitment to protect present and futu...
Source: Malaysian Medical Resources - November 13, 2015 Category: Global & Universal Authors: palmdoc Tags: Miscellaneous Source Type: blogs

What They Really Think of Us (Swiss Version) - Novartis CEO Would Not Commit to Changing Company Behavior After Latest of Multiple Legal Settlements
The huge corporations which now dominate global health care are creating amazing records of repeated ethical misadventures.  We last discussed multinational Swiss based pharmaceutical manufacturer Novartis' escapades in early 2014.   Since then, the legal settlements and other legal findings just keep on coming, capped with a big one in late October, 2015.We will summarize them in chronological order.Japanese Health, Labor and Welfare Ministry Found that Novartis Concealed Serious Adverse EffectsIn August, 2014, per the Japan Times, but apparently not reported widely outside of that country.Novartis Pharma K...
Source: Health Care Renewal - November 5, 2015 Category: Health Management Tags: corporate integrity agreement deception Express Scripts impunity kickbacks legal settlements Novartis Switzerland what they really think of us Source Type: blogs

In Memorium: Cathy Polley
Cathy Polley I was about three weeks into a new job in DC and my then boss told me she had a colleague of hers I had to meet. “She’s – you just have to meet her.” I followed my boss into a meeting some time later and there, for a brief moment, I met Cathy Polley for the first time. Cathy was bright, engaging, and her eloquent techniques for sharing hard data and evidence were only matched by her diplomatic grace that so few carry as a skill anymore.  I fast became a fan of her work and being. Our paths continued to cross throughout my time in that position and throughout the last several years I’m lucky enou...
Source: Disruptive Women in Health Care - November 5, 2015 Category: Consumer Health News Authors: dw at disruptivewomen.net Tags: Uncategorized Source Type: blogs

David Tuller responds to the PACE investigators
David Tuller’s three-installment investigation of the PACE trial for chronic fatigue syndrome, “Trial By Error,” has received enormous attention. Although the PACE investigators declined David’s efforts to interview them, they have now requested the right to reply. Today, virology blog posts their response to David’s story, and below, his response to their response.  According to the communications department of Queen Mary University, the PACE investigators have been receiving abuse on social media as a result of David Tuller’s posts. When I published Mr. Tuller’s articles, my intent was to provide a...
Source: virology blog - October 30, 2015 Category: Virology Authors: Vincent Racaniello Tags: Commentary Information adaptive pacing therapy CFS chronic fatigue syndrome clinical trial cognitive behavior therapy Dave Tuller exercise graded exercise therapy mecfs myalgic encephalomyelitis outcome PACE trial recovery Source Type: blogs

A rotation in Uganda provides perspective to this medical student
In May 2014, I gave my Grandma Lou a call to say goodbye before heading to Guatemala for two months of research. She took the opportunity to tell me her cancer had relapsed, and she didn’t think she wanted treatment. I was so anxious the entire trip that that phone call would be my final goodbye to Grammy but she conceded to my family’s pleading to receive treatment that was in post-marketing trials and she was doing well when I reached home. This summer, I stopped in to see her before taking off to Uganda. I joked about her making new friends in the assisted living center she would move into that weekend and told her ...
Source: Kevin, M.D. - Medical Weblog - October 27, 2015 Category: Journals (General) Authors: Tags: Education Medical school Source Type: blogs

How Pennsylvania is Screwing Radiologists
Here’s something new and different: Dino defending Radiologists. Oh, I’ve lit into them from time to time over the years, but we are colleagues. And a recent ruling by the Pennsylvania Governor’s office mandating that 3D mammograms, also known as tomosynthesis, be treated exactly the same as previous technology for payment purposes (ie “Free” to patients) is patently unfair to radiologists. Some background: The current technological standard for breast cancer mammography screening consists of taking plain low-dose xray images of compressed (ouch!) breast tissue, either with film or digital tec...
Source: Musings of a Dinosaur - October 21, 2015 Category: Primary Care Authors: notdeaddinosaur Tags: Medical Source Type: blogs

District Court Grants Permanent Injunction Against Device Maker
On Wednesday October 7, a federal judge in South Dakota granted the Food and Drug Administration (FDA) a permanent injunction against 2035 Inc. and Robert “Larry” Lytle, doing business as QLasers PMA and 2035 PMA. Interestingly, despite the “PMA” in the business name, the company had not in fact received PMA, or pre-market approval, from FDA before distributing their low-level laser devices. As a result, the government alleged that the devices are adulterated and misbranded within the meaning of the Federal Food, Drug & Cosmetic (FD&C) Act. According to the complaint for injunction filed on Oct. 21,...
Source: Policy and Medicine - October 13, 2015 Category: American Health Authors: Policy and Medicine Writing Staff Source Type: blogs

Healthcare Startups – Why Now and So What?
By LEONARD D’AVOLIO It’s 8:15 on Friday evening.  I’m almost through editing the job description for a user interface engineer after sending off an introductory slide deck to a potential client.  Today I met with a business development prospect, held calls with a potential advisor, a potential client, and finally made those changes to the website.  There’s not time to write this but when will there be? I’m part of a growing trend of academics, programmers, and clinicians taking the startup path to try to make healthcare a better place. In fact, record breaking amounts of venture funding are pouring into he...
Source: The Health Care Blog - October 9, 2015 Category: Consumer Health News Authors: Simon Nath Tags: THCB Leonard D’Avolio Source Type: blogs

Provider Payment Sunshine Act: Senators Grassley and Blumenthal Introduce Bill to Expand Open Payments Reporting Requirements to Nurse Practitioners and Physician Assistants
On October 7, Sen. Charles Grassley (R-Iowa) and Sen. Richard Blumenthal (D-Conn) introduced a bill that would expand the Open Payments reporting requirements to include nurse practitioners and physician assistants. Currently, to comply with the Sunshine Act, pharmaceutical and medical device manufacturers are required to report payments and other transfers of value to physicians and teachings hospitals. While the definition of physician is broad—and includes doctors of medicine, osteopathy, dentists, podiatrists, optometrists and chiropractors who legally authorized to practice by a state—the law currently does not co...
Source: Policy and Medicine - October 9, 2015 Category: American Health Authors: Policy and Medicine Writing Staff Source Type: blogs

Marcia Angell writes
By Marcia AngellIn 1953, a new drug was released by Burroughs Wellcome, a pharmaceutical company based in London. Pyrimethamine, as the compound was named, was originally intended to fight malaria after the microorganisms that cause the disease developed resistance to earlier therapies. The drug was used against malaria for several decades, often in combination with other compounds. It ’s mostly used now to treat toxoplasmosis, a parasitic infection that can be life-threatening in people whose immune systems are suppressed, for example, by HIV/​AIDS or cancer.More than 40 years later, Burroughs Wellcome merged with the...
Source: PharmaGossip - October 4, 2015 Category: Pharmaceuticals Authors: insider Source Type: blogs